Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells.
EGFR
MET
invadopodia
invasion
melanoma
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
31
05
2019
revised:
13
09
2019
accepted:
14
09
2019
pubmed:
23
10
2019
medline:
23
9
2020
entrez:
23
10
2019
Statut:
ppublish
Résumé
Epidermal and hepatocyte growth factors can stimulate invasive abilities of melanoma cells, while treatment with combination of their receptors' (EGFR and MET, respectively) inhibitors reduces viability of these cells, as we have previously shown. Proposed therapy has potential; however, used drugs block more than one goal effectively, what raises the question about the real target of analysed inhibitors. For this reason, we analysed direct involvement of these receptors in the invasion of melanoma cells inducing EGFR and MET up- and down-regulations in examined cells. Results were acquired with assays evaluating cell migration and invasion (scratch wound assay, Transwell filter-based method and single-cell tracking). We revealed that cells' motile abilities are increased after EGFR overexpression and decreased following EGFR and MET silencing. This outcome correlates with elevated (EGFR up-regulation) or reduced (EGFR/MET down-regulation) number of formed invadopodia, visualized with immunofluorescence, and their rate of proteolytic abilities, evaluated by fluorescent gelatin degradation assay, and gelatin zymography, compared to control cells. Above-mentioned data indicate that both-EGFR and MET signalling is directly connected with melanoma cells invasion, what establishes these receptors as promising targets for anti-cancer treatment.
Identifiants
pubmed: 31638339
doi: 10.1111/jcmm.14730
pmc: PMC6850915
doi:
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8453-8463Informations de copyright
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
Mol Cancer. 2018 Feb 19;17(1):26
pubmed: 29455657
Annu Rev Biochem. 2015;84:739-64
pubmed: 25621509
Clin Cancer Res. 2007 Apr 1;13(7):2246-53
pubmed: 17404109
Cancer Gene Ther. 2014 Nov;21(11):491-7
pubmed: 25394504
J Cell Biochem. 2011 Sep;112(9):2508-17
pubmed: 21557297
Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
pubmed: 21697900
Exp Cell Res. 2009 Feb 15;315(4):707-16
pubmed: 19022245
Front Pharmacol. 2015 Nov 24;6:283
pubmed: 26635612
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Oncotarget. 2016 Oct 25;7(43):69903-69915
pubmed: 27655711
Eur J Cell Biol. 2012 Nov-Dec;91(11-12):902-7
pubmed: 22658792
Biochem Biophys Res Commun. 2018 May 15;499(3):719-726
pubmed: 29605294
Ann Dermatol. 2011 Feb;23(1):33-8
pubmed: 21738360
Pigment Cell Melanoma Res. 2013 Jan;26(1):39-57
pubmed: 23095214
Oncotarget. 2018 Apr 6;9(26):18254-18268
pubmed: 29719603
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
PLoS One. 2014 May 09;9(5):e96718
pubmed: 24816687
Cancers (Basel). 2018 Sep 17;10(9):
pubmed: 30227653
J Surg Res. 2006 Nov;136(1):78-84
pubmed: 16950403
Int J Colorectal Dis. 2013 Jan;28(1):9-18
pubmed: 22733437
Oncotarget. 2017 May 30;8(22):36869-36884
pubmed: 28415812
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Ann Surg Oncol. 2016 Jun;23(6):2046-53
pubmed: 26812910
Eur J Cell Biol. 2014 Jan-Feb;93(1-2):23-9
pubmed: 24530009
Cancer Lett. 2009 Jul 18;280(1):78-85
pubmed: 19321255
J Mol Signal. 2010 Jul 12;5:8
pubmed: 20624308
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Oncotarget. 2016 Apr 19;7(16):21510-26
pubmed: 26909600
Eur J Histochem. 2016 Dec 09;60(4):2728
pubmed: 28076931
Oncogene. 2008 Jan 24;27(5):684-93
pubmed: 17684486
Mol Cancer. 2015 May 14;14:103
pubmed: 25971889
J Cell Sci. 2012 Jun 15;125(Pt 12):2940-53
pubmed: 22366451
Oncogene. 2012 May 3;31(18):2309-22
pubmed: 21909139
Oncol Lett. 2017 Feb;13(2):930-936
pubmed: 28356980
Biochimie. 2005 Mar-Apr;87(3-4):307-14
pubmed: 15781317
J Cutan Pathol. 2011 Jun;38(6):492-502
pubmed: 21352258
Mol Cancer Ther. 2011 Mar;10(3):518-30
pubmed: 21252284
Cancer Res. 2006 Mar 15;66(6):3034-43
pubmed: 16540652
Trends Cell Biol. 2007 Mar;17(3):107-17
pubmed: 17275303
Clin Exp Metastasis. 2009;26(4):273-87
pubmed: 18498004
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S37-50
pubmed: 22128287
Oncol Rep. 2017 Jun;37(6):3674-3680
pubmed: 28440510
Int J Cancer. 2007 Oct 15;121(8):1729-37
pubmed: 17594688
Cancer Res. 2011 Mar 1;71(5):1730-41
pubmed: 21257711
Oncol Lett. 2018 May;15(5):6131-6136
pubmed: 29616095
J Signal Transduct. 2010;2010:985132
pubmed: 21152266
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
pubmed: 388439
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Oncotarget. 2015 Apr 30;6(12):10086-101
pubmed: 25888626
Melanoma Res. 2012 Apr;22(2):123-32
pubmed: 22343486
J Immunol. 2012 Aug 15;189(4):1699-707
pubmed: 22802413
J Cell Mol Med. 2019 Dec;23(12):8453-8463
pubmed: 31638339